AMCP’s Post

Experts examine the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment. Watch the video series to learn more: https://bit.ly/3WdkGsj #ManagedCare #BreastCancer

Improving Self-Care Management in Patients with Breast Cancer through HiPaaS https://lnkd.in/gGWJjiM6

🔬 Exciting Progress in Pancreatic Cancer Treatment! 🌟 PanCAN's recent webinar, "Spotlight on Clinical Trials," provided invaluable insights into the latest advancements in pancreatic cancer clinical trials. Patients, caregivers, and loved ones learned about the importance of clinical trials at diagnosis and during treatment decisions. Missed it? Catch up on key takeaways and get answers to your burning questions about clinical trials, placebos, and more! 📖 Read more: https://lnkd.in/dBBR-VAU #PancreaticCancer #ClinicalTrials #CancerResearch #PanCAN

Dr. Pankaj Goyal, Senior Consultant, Medical Oncology at RGCIRC, recognized as one of the World’s Best Specialized Hospitals 2024 by Newsweek, stresses the critical importance of early diagnosis and timely treatment in the fight against breast cancer. His expertise highlights the value of regular self-examinations and scheduled screenings, particularly for women above 45, as these measures can identify potential issues early when treatment is most effective. Early detection is key to saving lives. Let us raise awareness and dispel misconceptions about breast cancer treatment. #RGCIRC #BreastCancerAwareness #EarlyDetection

We can act now to positively impact clinical research that leads to better treatment options for the women we love most. Participating in Lilly clinical trials for early-stage estrogen receptor positive and human epidermal receptor 2 negative (ER+/HER2-) breast cancer is one way to take action in finding better treatments. Start by learning more about Lilly clinical trials focused on advancing the treatment of breast cancer at https://e.lilly/49tmgtH. #MyStyleMatters #BlackHealthMatters #BreastCancerSurvivor #ClinicalTrials #BreastCancer #BreastCancerAwareness #CancerSupport #BreastCancerJourney #LifeAfterCancer #BlackWomenWithBreastCancer #CancerAwareness #BreastCancerWarrior #CancerFighter #PinkRibbon #SaveASister #BreastCancerResearch #IWishIKnew

Breast cancer myths are still widespread, even in healthcare. We need to arm ourselves with facts to help our patients. For example, there’s no evidence linking antiperspirants or bras to breast cancer risk. What are the common myths you encounter in your practice, and how do you address them? #MythBusting #BreastCancerFacts #PatientEducation ##MedicalMarketing #HealthcareMarketing #SouthAfrica

In this #PeerExchange, experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. Learn more about the groundbreaking treatments here: https://bit.ly/3WdkGsj #BreastCancer

A new blood test, called a liquid biopsy, has been revealed as a breakthrough in preventing breast cancer recurrence. It can predict if breast cancer will return years before the disease shows up on scans. Professor Cliona Kirwan, Chair of the Prevent Breast Cancer Scientific Advisory Board said: 🗣️ "This is a really important development for women who have undergone treatment for early breast cancer as it will potentially increase their chances of living longer, healthier lives.” Read the full story by our Trusts and Research Officer Eva Hughes 👇 https://lnkd.in/e84FhJwz #breastcancer #cancerresearch #breastcancerrecurrence #medical #healthcare #womenshealth #breastcancerprevention

📣Breakthroughs ahead in cancer therapy! Get ready for innovative anti-TIGIT treatments transforming patient outcomes. From enhancing immune response to precise targeting, look forward to promising outcomes. Please read our full whitepaper here - 🌐 https://lnkd.in/gmGzA86H #TIGIT,#Immunology,#Oncology,#Roche,#Arcus,#Merck,#Immunecheckpointinhibitors,#Cancerimmunotherapy,#Monoclonalantibodies,#Tcellregulation,#Clinicaltrials,#Cancertreatment,#Pharmaceuticalresearch,#Biomarkers,#Drugdevelopment,#Immuneresponse,#Tumormicroenvironment

Treatment of hormone receptor-positive (HR+) #BreastCancer has become increasingly more complex with the expansion of treatment options in both early and advanced disease alongside the need to personalize decision-making based on tumor-specific and clinical factors as well as patient-related considerations. Join PeerView Live, GRASP , and Living Beyond Breast Cancer at the #ASCO24 Annual Meeting for a “Candid Conversations & Clinical Consults” educational symposium, where expert panelists will provide guidance on navigating the most recent evidence and evolving best practice recommendations for risk assessment, predictive/prognostic testing, and selection and sequencing of therapies in HR+ EBC and MBC, while offering a practical framework for making clinical decisions with maximum impact on patient outcomes in real-world settings, especially in community oncology practice. Real-world cases will be used to demonstrate how to best apply evidence to practice in straightforward and more complex, challenging scenarios. We hope to see you on Sunday, June 2, at 6:30 PM CDT, live in Chicago or virtually to help you take your breast cancer patient care to the next level! #ASCO2024 https://lnkd.in/eyf3bPad #MedEd #Oncology This activity is supported by independent educational grants from AstraZeneca, Genentech and Eli Lilly and Company